Key result
A novel bivalent CMV vaccine formulated with CMVpoly and gB proteins and CpG1018 adjuvant induced robust and durable CMV-specific CD4+ and CD8+ T cell responses and neutralizing antibodies in multiple HLA expressing mice.
Why the study?
Successful development of an effective CMV vaccine requires improved formulation and adjuvant selection capable of inducing both humoral and cellular immune responses.
Does a bivalent CMV vaccine formulated with TLR9 agonist CpG1018 elicit cellular and humoral immunity in HLA expressing mice?
Does a bivalent CMV vaccine formulated with TLR9 agonist CpG1018 elicit cellular and humoral immunity in HLA expressing mice?
A novel bivalent CMV subunit vaccine with CpG1018 adjuvant elicits robust and durable humoral and cellular immune responses in a preclinical mouse model.
Supports advancing this bivalent CMV vaccine to human trials; leaves open clinical immunogenicity and efficacy.
There is now convincing evidence that the successful development of an effective CMV vaccine will require improved formulation and adjuvant selection that is capable of inducing both humoral and cellular immune responses. Here, we have designed a novel bivalent subunit vaccine formulation based on CMV-encoded oligomeric glycoprotein B (gB) and polyepitope protein in combination with human compatible TLR9 agonist CpG1018. The polyepitope protein includes multiple minimal HLA class I-restricted CD8 + T cell epitopes from different antigens of CMV. This subunit vaccine generated durable anti-viral antibodies, CMV-specific CD4 + and CD8 + T cell responses in multiple HLA expressing mice. Antibody responses included broad T H 1 isotypes (IgG2a, IgG2b and IgG3) and potently neutralized CMV infection in fibroblasts and epithelial cells. Furthermore, polyfunctional antigen-specific T cell immunity and antiviral antibody responses showed long-term memory maintenance. These observations argue that this novel vaccine strategy, if applied to humans, could facilitate the generation of robust humoral and cellular immune responses which may be more effective in preventing CMV-associated complications in various clinical settings.
No takes yet. Share an insight, caveat, or question.
Dasari et al. (2022) studied Cytomegalovirus (CMV) infection. Bivalent CMV vaccine (CMVpoly and gB proteins with CpG1018 adjuvant) vs. CpG1018 adjuvant alone (placebo) was evaluated on CMV-specific cellular (CD4+ and CD8+ T cells) and humoral (neutralizing antibodies) immune responses. A novel bivalent CMV vaccine formulated with CMVpoly and gB proteins and CpG1018 adjuvant induced robust and durable CMV-specific CD4+ and CD8+ T cell responses and neutralizing antibodies in multiple HLA expressing mice.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: